Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Total Current Liabilities (2023 - 2025)

Compass Therapeutics' Total Current Liabilities history spans 3 years, with the latest figure at $14.0 million for Q4 2025.

  • For Q4 2025, Total Current Liabilities rose 57.4% year-over-year to $14.0 million; the TTM value through Dec 2025 reached $14.0 million, up 57.4%, while the annual FY2025 figure was $14.0 million, 57.4% up from the prior year.
  • Total Current Liabilities for Q4 2025 was $14.0 million at Compass Therapeutics, up from $12.4 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $14.9 million in Q1 2025 and bottomed at $3.9 million in Q1 2024.
  • The 3-year median for Total Current Liabilities is $9.6 million (2023), against an average of $10.0 million.
  • The largest annual shift saw Total Current Liabilities plummeted 65.21% in 2024 before it skyrocketed 282.74% in 2025.
  • A 3-year view of Total Current Liabilities shows it stood at $7.8 million in 2023, then rose by 13.75% to $8.9 million in 2024, then skyrocketed by 57.4% to $14.0 million in 2025.
  • Per Business Quant, the three most recent readings for CMPX's Total Current Liabilities are $14.0 million (Q4 2025), $12.4 million (Q3 2025), and $13.9 million (Q2 2025).